State Board Of Administration Of Florida Retirement System Has Cut Seattle Genetics (SGEN) Stake by $1.01 Million; Stock Declined; As Merck & Co New Com (MRK) Share Price Declined, Sva Plumb Wealth Management Cut Its Position by $359,016

May 18, 2018 - By Richard Conner

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo

Sva Plumb Wealth Management Llc decreased its stake in Merck & Co Inc New Com (MRK) by 7.67% based on its latest 2017Q4 regulatory filing with the SEC. Sva Plumb Wealth Management Llc sold 6,411 shares as the company’s stock declined 4.63% with the market. The institutional investor held 77,134 shares of the health care company at the end of 2017Q4, valued at $4.34M, down from 83,545 at the end of the previous reported quarter. Sva Plumb Wealth Management Llc who had been investing in Merck & Co Inc New Com for a number of months, seems to be less bullish one the $159.55B market cap company. The stock increased 0.40% or $0.235 during the last trading session, reaching $59.305. About 846,237 shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since May 18, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.




State Board Of Administration Of Florida Retirement System decreased its stake in Seattle Genetics Inc (SGEN) by 11.36% based on its latest 2017Q4 regulatory filing with the SEC. State Board Of Administration Of Florida Retirement System sold 19,090 shares as the company’s stock declined 4.17% with the market. The institutional investor held 148,933 shares of the health care company at the end of 2017Q4, valued at $7.97M, down from 168,023 at the end of the previous reported quarter. State Board Of Administration Of Florida Retirement System who had been investing in Seattle Genetics Inc for a number of months, seems to be less bullish one the $9.07 billion market cap company. The stock increased 0.02% or $0.01 during the last trading session, reaching $57.34. About 14,483 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 20.48% since May 18, 2017 and is downtrending. It has underperformed by 32.03% the S&P500.

Since December 11, 2017, it had 3 insider buys, and 10 insider sales for $268.25 million activity. 10,457 shares valued at $552,452 were sold by DRACHMAN JONATHAN G on Monday, March 5. BAKER BROS. ADVISORS LP bought $24.57 million worth of stock. 18,832 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $1.04 million were sold by SIEGALL CLAY B. $290,604 worth of stock was sold by HIMES VAUGHN B on Thursday, March 15.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Seattle Genetics had 67 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Overweight” rating by Barclays Capital on Wednesday, July 27. As per Tuesday, November 29, the company rating was downgraded by Barclays Capital. The company was maintained on Monday, November 13 by RBC Capital Markets. The firm has “Hold” rating by Cantor Fitzgerald given on Monday, June 19. The stock has “Hold” rating by Cantor Fitzgerald on Wednesday, August 16. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Overweight” rating by Barclays Capital on Thursday, February 4. The rating was maintained by Cowen & Co on Thursday, July 27 with “Hold”. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Hold” rating given on Tuesday, August 29 by Cantor Fitzgerald. Goldman Sachs initiated the shares of SGEN in report on Wednesday, November 18 with “Sell” rating. The stock has “Outperform” rating by RBC Capital Markets on Monday, September 14.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on April 27, 2018, also Businesswire.com with their article: “Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting” published on May 17, 2018, Seekingalpha.com published: “Seattle Genetics (SGEN) Q1 2018 Results – Earnings Call Transcript” on April 27, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags …” published on May 09, 2018 as well as Seekingalpha.com‘s news article titled: “Seattle Genetics Fairly Valued, Pending Data” with publication date: May 14, 2018.

State Board Of Administration Of Florida Retirement System, which manages about $37.66B US Long portfolio, upped its stake in Bright Horizons Fam Sol In D (NYSE:BFAM) by 5,555 shares to 52,003 shares, valued at $4.89M in 2017Q4, according to the filing. It also increased its holding in Peabody Energy Corp New by 8,960 shares in the quarter, for a total of 17,649 shares, and has risen its stake in Lpl Finl Hldgs Inc (NASDAQ:LPLA).

Investors sentiment increased to 1.23 in Q4 2017. Its up 0.45, from 0.78 in 2017Q3. It is positive, as 24 investors sold SGEN shares while 67 reduced holdings. 44 funds opened positions while 68 raised stakes. 141.83 million shares or 1.14% more from 140.23 million shares in 2017Q3 were reported. Sei Invs accumulated 0% or 13,379 shares. Bancorporation Of America De invested in 453,495 shares. Strs Ohio owns 1,235 shares for 0% of their portfolio. 12,600 were accumulated by Nomura Asset Mngmt. Griffin Asset Mngmt reported 4,775 shares. Qs Limited stated it has 3,511 shares or 0% of all its holdings. Pinnacle Assoc Limited has 930,673 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 24,753 shares. Tower Rech Lc (Trc) stated it has 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). 15,709 were reported by State Of Wisconsin Invest Board. Parametric Portfolio Assoc Limited Liability Corp has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Opus Point Prtnrs Mngmt Ltd Co holds 1.65% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 35,668 shares. Teacher Retirement System Of Texas accumulated 27,125 shares or 0.01% of the stock. The Ohio-based Keybank Natl Association Oh has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Art Advsr Lc has 0.1% invested in Seattle Genetics, Inc. (NASDAQ:SGEN).

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on July, 26. They expect $-0.36 EPS, up 7.69% or $0.03 from last year’s $-0.39 per share. After $-0.61 actual EPS reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts -40.98% EPS growth.

Among 24 analysts covering Merck & Co. Inc. (NYSE:MRK), 21 have Buy rating, 0 Sell and 3 Hold. Therefore 88% are positive. Merck & Co. Inc. had 90 analyst reports since August 13, 2015 according to SRatingsIntel. The stock has “Buy” rating by SunTrust on Tuesday, January 16. The stock has “Buy” rating by Berenberg on Tuesday, November 24. Leerink Swann upgraded the stock to “Buy” rating in Monday, March 12 report. The firm has “Equal-Weight” rating by Barclays Capital given on Monday, October 30. BMO Capital Markets maintained the shares of MRK in report on Thursday, April 26 with “Outperform” rating. UBS maintained Merck & Co., Inc. (NYSE:MRK) on Monday, July 31 with “Buy” rating. The firm earned “Buy” rating on Monday, October 30 by Citigroup. Bank of America maintained it with “Buy” rating and $64 target in Tuesday, November 28 report. On Monday, July 17 the stock rating was maintained by Jefferies with “Sell”. The firm has “Buy” rating given on Tuesday, April 17 by Bank of America.

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.12, from 1.06 in 2017Q3. It is negative, as 94 investors sold MRK shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported. Notis holds 0.74% or 22,830 shares in its portfolio. First Bank & Trust Of Newtown accumulated 49,877 shares. Hightower Limited holds 0.72% or 1.56 million shares in its portfolio. The Illinois-based Ativo Capital Management Ltd Liability has invested 0.29% in Merck & Co., Inc. (NYSE:MRK). Cadinha And Company Ltd Company has invested 0.18% in Merck & Co., Inc. (NYSE:MRK). Qcm Cayman Limited accumulated 8,958 shares. Yhb Investment Advsrs owns 0.15% invested in Merck & Co., Inc. (NYSE:MRK) for 15,867 shares. Transamerica Financial Advsr has 20,606 shares. The California-based Checchi Capital Advisers Limited Liability has invested 0.19% in Merck & Co., Inc. (NYSE:MRK). Klingenstein Fields & Commerce Limited Liability stated it has 0.92% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Oppenheimer & holds 0.38% or 265,605 shares. Planning Advisors Ltd holds 3,820 shares. Hays Advisory Limited Com owns 5,810 shares for 0.12% of their portfolio. Roffman Miller Pa owns 15,848 shares for 0.11% of their portfolio. Allsquare Wealth Management Lc reported 4,052 shares.

Sva Plumb Wealth Management Llc, which manages about $1.95 billion and $852.83M US Long portfolio, upped its stake in Schwab Us Mid (SCHM) by 25,307 shares to 1.50M shares, valued at $79.91M in 2017Q4, according to the filing. It also increased its holding in Pimco Etf Tr 0 (HYS) by 8,649 shares in the quarter, for a total of 10,788 shares, and has risen its stake in Schwab Us Dividend Equity Etf (SCHD).

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on July, 27. They expect $1.04 earnings per share, up 2.97% or $0.03 from last year’s $1.01 per share. MRK’s profit will be $2.80B for 14.26 P/E if the $1.04 EPS becomes a reality. After $1.05 actual earnings per share reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts -0.95% negative EPS growth.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Seekingalpha.com which released: “Merck: Getting Stronger” on May 04, 2018, also Streetinsider.com with their article: “Dr. Roger Dansey Departure at Merck (MRK) an ‘Incrementally Negative’ – BMO” published on May 17, 2018, Seekingalpha.com published: “New Ebola outbreak hits Congo” on May 13, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Streetinsider.com and their article: “Morgan Finds Positive Datapoints For MRK and BMY At ASCO” published on May 17, 2018 as well as Fool.com‘s news article titled: “Better Buy: Pfizer Inc. (PFE) vs. Merck (MRK)” with publication date: May 13, 2018.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: